Psychotomimetic agent BZ (3-Quinuclidinyl Benzilate)

Handbook of Toxicology of Chemical Warfare Agents

Volumn , Issue , 2009, Pages 135-142

  Fusek, Josef ^a   Bajgar, Jiri ^a   Kassa, Jiri ^a   Kuca, Kamil ^a,b   Jun, Daniel ^a,b  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884796691     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374484-5.00010-9     Document Type: Chapter

References (31)

1. Albanus L. Central and peripheral effects of anticholinergic compounds. Acta Pharmacol. Toxicol 1970, 28:305-326.
2. Albert, A. (1966). The Acridines, p. 604. Wiliam Clowes and Sons, London and Beccles.
3. Aleksandrov V.N., Emelyanov V.I. Otravlyayushchie veshchestva 1990, Voennoe izdatelstvo, Moscow, p. 272.
4. Filip V., Vachek J., Albrecht V., Dvorak I., Dvorakova J., Fusek J., Havlu J. Pharmacokinetics and tolerance of 7-methoxytacrine following single dose administration in healthy volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol 1991, 29:431-436.
5. Fusek J. Tacrin and its analogues, antidotes against psychotomimetics with anticholinergic effects. Voj. Zdrav. Listy 1977, 46:21-27. Czech.
6. Fusek J., Kabes J., Fink Z. Peripheral effects of anticholinergic psychotomimetics. Activ. Nerv. Sup 1971, 13:191-193.
7. Fusek J., Patocka J., Bajgar J., Bielavsky J., Herink J., Hrdina V. 4,-tetrahydro-9-amino-acridine. Activ. Nerv. Sup 1974, 16:226-228. Pharmacology of 1,2,3.
8. Fusek J., Herink J., Koupilova M., Patocka J., Bajgar J., Hrdina V. The interaction of anticholinesterases and diazepam in the treatment of anticholinergic syndrome in dogs. Activ. Nerv. Sup. 1979, 21:183-184.
9. Fusek J., Patocka J., Bajgar J., Koupilova M., Hrdina V. Anticholinesterase effects of 9-amino-7-methoxy-1,2,3,4-tetrahydroacridine. Activ. Nerv. Sup 1986, 28:327-328.
10. Gershon S., Angrist B.M. Effects of alterations of cholinergic function on behavior. In Proceedings of the 62nd Annual Meeting of the American Psychopathological Association. Chapt 1973, 2. John Hopkins Press, Baltimore, pp. 15-36.
11. Gershon S., Olariu J. JB 329-a new psychotomimetic. Its antagonism by tetrahydroaminacrine and its comparison with LSD, mescaline, and sernyl. J. Neuropsychiatry 1960, 1:283-292.
12. Halamek E., Kobliha Z. Investigation of the conditions of extraction of ion-associates of 3-quinuclidinyl benzilate with acidic dyes. Collect. Czech. Chem. Commun 1993, 58:315-319.
13. Hoffman A. Psychotomimetics: chemical, pharmacological and medical aspects. Svensk. Chem. Tidskr. 1960, 72:723-747.
14. Hollister L.E. Chemical Psychoses. LSD and Related Drugs 1968, Charles C. Thomas, Springfield, p. 190.
15. Itil T., Fink M. Anticholinergic drug-induced delirium: experimental modification, quantitative EEG and behavioral correlations. J. Nerv. Ment. Dis 1966, 143:492-507.
16. Jovic R.C., Zupanc S. Inhibition of stimulated cerebral respiration in vitro and oxygen consumption in vivo in rats treated by cholinolytic drugs. Biochem. Pharmacol 1973, 22:1189-1194.
17. Ketchum, J.S., Sidell, F.R. (1997). Incapacitating agents. In Textbook of Military Medicine, Warfare, Weaponry, and the Causality: Medical Aspects of Chemical and Biological Warfare, Part 1, pp. 287-306. The Office of the Surgeon General and TMM Publications. Borden Institute, Walter Reed Army Medical Center, Washington DC.
18. Ketchum J.S., Sidell F.R., Crowell E.B., Aghajanian G.K., Hayes A.H. Atropine, scopolamine, and ditrane: comparative pharmacology and antagonists in man. Psychopharmacologia (Berlin) 1973, 28:121-145.
19. Lefkowitz R.J. Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci. 2004, 22:413-422.
20. Marx J.L. Alzheimer's drug trial put on hold. Science 1987, 238:1041-1065.
21. Monica F.Z.T., Bricola A.A.O., Bau F.R., Freitas L.L.L., Teixeira S.A., Muscara M.N., Abdalla F.M.F., Porto C.S., De Nucci G., Zanesco A., Antunes E. Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces beta(3)-andrenoceptor-mediated relaxation, causing rat detrusor overactivity. Br. J. Pharmacol 2008, 153:1659-1668.
22. Parkasi S., Colloby S.J., Firnbank M.J., Perry E.K., Wyper D.J., Owens J., McKeith I.G., William E.D., O'Brien J.T. Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R)123I-QNB SPECT. J. Neurol 2007, 254:907-913.
23. Patocka J., Bielavsky J., Cabal J. Identification of 9-amino-7-hydroxy-1,2,3,4-tetrahydroaminoacridine as a major metabolite of 7-methoxytacrine. Chem. Listy 1996, 90:753-754.
24. Pearson A. Incapacitating biochemical weapons. Science, technology, and policy for the 21st century. Nonprolifer. Rev. 2006, 13:152-188.
25. Sidell, F.R. (1982). Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents. Vol. 1. Anticholinesterases and Anticholinergics (Panel on Anticholinesterase Chemicals, Panel on Anticholinergic Chemicals, Committee on Toxicology, Board on Toxicology and Environmental Health Hazards, eds), pp. xiv, 284. National Academy Press, Washington DC.
26. Sidell F.R., Aghajanian G.K., GroffW.A. The reversal of anticholinergic intoxication in man with cholinesterase inhibitor VX. Proc. Soc. Exp. Biol. Med 1973, 144:725-730.
27. Skalican Z., Halamek E., Kobliha Z. Study of the potential of thin-layer chromatographic identification of psychotropic drugs in field analysis. J. Planar. Chromatogr 1997, 10:208-216.
28. Spivak L.I., Milstejn G.I. Problemy psichotoksikologii. Voj. med. Z 1973, 10:40-44.
29. Wyper D.J., Brown D., Patterson J., Owens J., Hunter R., Teasdale E., McCulloch J. Deficits in iodine-labelled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzeheimer's disease. Eur. J. Nucl. Med 1993, 20:379-386.
30. Yamada, M., Chiba, T., Sasabe, J., Terashita, K., Aiso, S., Matsuoka, M., Chiba, T., Matsuoka, M. (2007). Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease. Neuropsychopharmacology advance online publication, October 10, 2007; doi: 10.1038/sj.npp.1301591. http://www.nature.com/npp/journal/vaop/ncurrent/full/1301591a.html.
31. Zapletalek M., Hanus H., Fusek J., Hrdina V. First experiences with 7-methoxytacrine administration to psychic patients. Cs. Psychiat 1989, 85:155-164. Czech.